These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

425 related articles for article (PubMed ID: 10945494)

  • 1. Multiple molecular marker testing (p53, C-Ki-ras, c-erbB-2) improves estimation of prognosis in potentially curative resected non-small cell lung cancer.
    Schneider PM; Praeuer HW; Stoeltzing O; Boehm J; Manning J; Metzger R; Fink U; Wegerer S; Hoelscher AH; Roth JA
    Br J Cancer; 2000 Aug; 83(4):473-9. PubMed ID: 10945494
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel molecular staging protocol for non-small cell lung cancer.
    Miyake M; Adachi M; Huang C; Higashiyama M; Kodama K; Taki T
    Oncogene; 1999 Apr; 18(14):2397-404. PubMed ID: 10327061
    [TBL] [Abstract][Full Text] [Related]  

  • 3. P53 mutational status improves estimation of prognosis in patients with curatively resected adenocarcinoma in Barrett's esophagus.
    Schneider PM; Stoeltzing O; Roth JA; Hoelscher AH; Wegerer S; Mizumoto S; Becker K; Dittler HJ; Fink U; Siewert JR
    Clin Cancer Res; 2000 Aug; 6(8):3153-8. PubMed ID: 10955797
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Altered retinoblastoma protein expression in nonsmall cell lung cancer: its synergistic effects with altered ras and p53 protein status on prognosis.
    Dosaka-Akita H; Hu SX; Fujino M; Harada M; Kinoshita I; Xu HJ; Kuzumaki N; Kawakami Y; Benedict WF
    Cancer; 1997 Apr; 79(7):1329-37. PubMed ID: 9083154
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutations in exon 7 and 8 of p53 as poor prognostic factors in patients with non-small cell lung cancer.
    Huang C; Taki T; Adachi M; Konishi T; Higashiyama M; Miyake M
    Oncogene; 1998 May; 16(19):2469-77. PubMed ID: 9627113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: a Southwest Oncology Group study.
    Ahnen DJ; Feigl P; Quan G; Fenoglio-Preiser C; Lovato LC; Bunn PA; Stemmerman G; Wells JD; Macdonald JS; Meyskens FL
    Cancer Res; 1998 Mar; 58(6):1149-58. PubMed ID: 9515799
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation of different markers (p53, EGF-R, c-erbB-2, Ki-67) expression in the diagnostic biopsies and the corresponding resected tumors in non-small cell lung cancer.
    Meert AP; Martin B; Verdebout JM; Paesmans M; Berghmans T; Ninane V; Sculier JP
    Lung Cancer; 2004 Jun; 44(3):295-301. PubMed ID: 15140542
    [TBL] [Abstract][Full Text] [Related]  

  • 8. APC, K-ras, and p53 gene mutations in colorectal cancer patients: correlation to clinicopathologic features and postoperative surveillance.
    Hsieh JS; Lin SR; Chang MY; Chen FM; Lu CY; Huang TJ; Huang YS; Huang CJ; Wang JY
    Am Surg; 2005 Apr; 71(4):336-43. PubMed ID: 15943410
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic significance of ER, PR, Ki67, c-erbB-2, and p53 in endometrial carcinoma.
    Suthipintawong C; Wejaranayang C; Vipupinyo C
    J Med Assoc Thai; 2008 Dec; 91(12):1779-84. PubMed ID: 19133508
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Do molecular markers predict survival in non-small-cell lung cancer?
    Greatens TM; Niehans GA; Rubins JB; Jessurun J; Kratzke RA; Maddaus MA; Niewoehner DE
    Am J Respir Crit Care Med; 1998 Apr; 157(4 Pt 1):1093-7. PubMed ID: 9563724
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Localized adenocarcinoma of the lung: oncogene expression of erbB-2 and p53 in 150 patients.
    Harpole DH; Marks JR; Richards WG; Herndon JE; Sugarbaker DJ
    Clin Cancer Res; 1995 Jun; 1(6):659-64. PubMed ID: 9816029
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship of p53 and c-erbB-2 expression to histopathological features, Helicobacter pylori infection and prognosis in gastric cancer.
    Shun CT; Wu MS; Lin JT; Chen SY; Wang HP; Lee WJ; Wang TH; Chuang SM
    Hepatogastroenterology; 1997; 44(14):604-9. PubMed ID: 9164544
    [TBL] [Abstract][Full Text] [Related]  

  • 13. p53 null mutations undetected by immunohistochemical staining predict a poor outcome with early-stage non-small cell lung carcinomas.
    Hashimoto T; Tokuchi Y; Hayashi M; Kobayashi Y; Nishida K; Hayashi S; Ishikawa Y; Tsuchiya S; Nakagawa K; Hayashi J; Tsuchiya E
    Cancer Res; 1999 Nov; 59(21):5572-7. PubMed ID: 10554037
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EGFR, c-erbB-2 and ki-67 in NSCLC and preneoplastic bronchial lesions.
    Meert AP; Martin B; Verdebout JM; Feoli F; Mascaux C; Ninane V; Sculier JP
    Anticancer Res; 2006; 26(1A):135-8. PubMed ID: 16475689
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TP53 mutational pattern in Spanish and Polish non-small cell lung cancer patients: null mutations are associated with poor prognosis.
    de Anta JM; Jassem E; Rosell R; Martínez-Roca M; Jassem J; Martínez-López E; Monzó M; Sánchez-Hernández JJ; Moreno I; Sánchez-Céspedes M
    Oncogene; 1997 Dec; 15(24):2951-8. PubMed ID: 9416838
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of K-ras and p53 mutations in bronchoscopically obtained malignant and non-malignant tissue from patients with non-small cell lung cancer.
    Lang SM; Stratakis DF; Freudling A; Ebelt K; Oduncu F; Hautmann H; Huber RM
    Eur J Med Res; 2000 Aug; 5(8):341-6. PubMed ID: 10958767
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Prognostic value of expression of FASE, HER-2/neu, bcl-2 and p53 in stage I non-small cell lung cancer].
    Wang Y; Zhang XR; Fu J; Tan W; Zhang W
    Zhonghua Zhong Liu Za Zhi; 2004 Jun; 26(6):369-72. PubMed ID: 15312350
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GSTM1, P53 and K-ras molecular detection in resectable non-small cell lung cancer by denaturing gradient gel electrophoresis-bronchoalveolar lavage fluid analysis.
    Curigliano G; Ferretti G; Mandalà M; De Pas T; Calabrò MG; Solli P; Noberasc C; de Braud F
    Anticancer Res; 2001; 21(5):3461-9. PubMed ID: 11848510
    [TBL] [Abstract][Full Text] [Related]  

  • 19. P53 and K-ras mutations are frequent events in microscopically negative surgical margins from patients with nonsmall cell lung carcinoma.
    Jassem J; Jassem E; Jakóbkiewicz-Banecka J; Rzyman W; Badzio A; Dziadziuszko R; Kobierska-Gulida G; Szymanowska A; Skrzypski M; Zylicz M
    Cancer; 2004 May; 100(9):1951-60. PubMed ID: 15112277
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Promoter hypermethylation of RASSF1A and RUNX3 genes as an independent prognostic prediction marker in surgically resected non-small cell lung cancers.
    Yanagawa N; Tamura G; Oizumi H; Kanauchi N; Endoh M; Sadahiro M; Motoyama T
    Lung Cancer; 2007 Oct; 58(1):131-8. PubMed ID: 17606310
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.